Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: SusieQ1065 who wrote (7418)	7/19/2001 4:21:55 PM
From: SusieQ1065	Read Replies (1) \| Respond to of 208838

IDEC Pharm (IDPH) 51.60 -1.17: Reports Q2 earnings of $0.15 a share, in line with the First Call consensus of $0.15, vs year-ago earnings of $0.09; revenues rose to $64.8 mln from $39.0 mln year-ago; $58.1 mln of revenues were from company's joint arrangement with Genentech (DNA) for the sale of Rituxan. PMC-Sierra (PMCS) 31.30 +2.30: Company reports Q2 net loss of $0.08 per share, in line with consensus; reports Q4 revs of $94.1 mln vs. consensus of $93.2 mln; "current revenue trends are a direct result of inventory build up in the supply chain but data points indicate that inventory is burning off at our customers and the contract manufacturers." see press release.